Sensei Biotherapeutics Inc

Item 5. Other Information.

Plan of Termination

On November 12, 2024, our board of directors approved a plan to reduce our current workforce by approximately 46% to decrease operating expenses, streamline operations and focus resources on advancing the clinical development of SNS-101. We expect the reduction in force to be substantially completed by the end of 2024. As a result, we estimate that we will incur a one-time charge of approximately $0.7 million in connection with one-time employee termination costs, including severance and other benefits. This charge is expected to be incurred during the fourth quarter of 2024.

The estimates of costs that we expect to incur and the timing thereof are subject to a number of assumptions and actual results may differ.

Rule 10b5-1 Trading Plans

From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading plans (as each such term is defined in Item 408 of Regulation S-K). The trading plans are intended to satisfy the affirmative defense in Rule 10b5-1(c). During the three months ended September 30, 2024, none of our directors or officers adopted, modified or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading plan.